Stroma Targeting Nuclear Imaging and Radiopharmaceuticals

Overview

Journal Int J Mol Imaging

Date 2012 Jun 12

PMID 22685650

Citations 1

Authors

Dinesh Shetty

Jae-Min Jeong

Hyunsuk Shim

Affiliations

Soon will be listed here.

Abstract

Malignant transformation of tumor accompanies profound changes in the normal neighboring tissue, called tumor stroma. The tumor stroma provides an environment favoring local tumor growth, invasion, and metastatic spreading. Nuclear imaging (PET/SPECT) measures biochemical and physiologic functions in the human body. In oncology, PET/SPECT is particularly useful for differentiating tumors from postsurgical changes or radiation necrosis, distinguishing benign from malignant lesions, identifying the optimal site for biopsy, staging cancers, and monitoring the response to therapy. Indeed, PET/SPECT is a powerful, proven diagnostic imaging modality that displays information unobtainable through other anatomical imaging, such as CT or MRI. When combined with coregistered CT data, [(18)F]fluorodeoxyglucose ([(18)F]FDG)-PET is particularly useful. However, [(18)F]FDG is not a target-specific PET tracer. This paper will review the tumor microenvironment targeting oncologic imaging such as angiogenesis, invasion, hypoxia, growth, and homing, and also therapeutic radiopharmaceuticals to provide a roadmap for additional applications of tumor imaging and therapy.

Citing Articles

New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions.

Smith G, Carroll L, Aboagye E Mol Imaging Biol. 2012; 14(6):653-66.

PMID: 22948535 DOI: 10.1007/s11307-012-0590-y.

References

Jiang L, Miao Z, Kimura R, Liu H, Cochran J, Culter C . Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2010; 38(4):613-22. DOI: 10.1007/s00259-010-1684-x. View

Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li S . Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des. 2002; 8(20):1781-807. DOI: 10.2174/1381612023393756. View

Hu M, Scollard D, Chan C, Chen P, Vallis K, Reilly R . Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF. Nucl Med Biol. 2007; 34(8):887-96. DOI: 10.1016/j.nucmedbio.2007.06.010. View

Parliament M, Chapman J, Urtasun R, McEwan A, GOLBERG L, Mercer J . Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer. 1992; 65(1):90-5. PMC: 1977349. DOI: 10.1038/bjc.1992.17. View

Blasi F, Carmeliet P . uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002; 3(12):932-43. DOI: 10.1038/nrm977. View

Haubner R, Wester H, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman S . Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001; 42(2):326-36. View

Ceradini D, Kulkarni A, Callaghan M, Tepper O, Bastidas N, Kleinman M . Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10(8):858-64. DOI: 10.1038/nm1075. View

Beer A, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik P . Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med. 2008; 49(2):255-9. DOI: 10.2967/jnumed.107.045526. View

Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T . Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 1993; 53(22):5365-9. View

10.

Dehdashti F, Grigsby P, Lewis J, Laforest R, Siegel B, Welch M . Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2008; 49(2):201-5. DOI: 10.2967/jnumed.107.048520. View

11.

Jacobson O, Weiss I, Szajek L, Niu G, Ma Y, Kiesewetter D . PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics. 2011; 1:251-62. PMC: 3085282. DOI: 10.7150/thno/v01p0251. View

12.

de Jong M, Bakker W, Krenning E, Breeman W, van der Pluijm M, Bernard B . Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997; 24(4):368-71. DOI: 10.1007/BF00881807. View

13.

Postema E, McEwan A, Riauka T, Kumar P, Richmond D, Abrams D . Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA). Eur J Nucl Med Mol Imaging. 2009; 36(10):1565-73. DOI: 10.1007/s00259-009-1154-5. View

14.

Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher D, Liu S . microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005; 46(10):1707-18. View

15.

Sternlicht M, Werb Z . How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17:463-516. PMC: 2792593. DOI: 10.1146/annurev.cellbio.17.1.463. View

16.

de Jong M, Breeman W, Bernard B, Bakker W, Schaar M, van Gameren A . [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001; 92(5):628-33. DOI: 10.1002/1097-0215(20010601)92:5<628::aid-ijc1244>3.0.co;2-l. View

17.

Brooks P, Montgomery A, Rosenfeld M, Reisfeld R, Hu T, Klier G . Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994; 79(7):1157-64. DOI: 10.1016/0092-8674(94)90007-8. View

18.

Cai W, Wu Y, Chen K, Cao Q, Tice D, Chen X . In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res. 2006; 66(19):9673-81. DOI: 10.1158/0008-5472.CAN-06-1480. View

19.

Nimmagadda S, Pullambhatla M, Pomper M . Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med. 2009; 50(7):1124-30. PMC: 3075860. DOI: 10.2967/jnumed.108.061325. View

20.

Baum R, Rosch F . 1 World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23-26, 2011, Zentralklinik Bad Berka, Germany. World J Nucl Med. 2011; 10(1):1-2. PMC: 3198045. DOI: 10.4103/1450-1147.82105. View